DehydraTECH for Antivirals
Viral Infections
PreclinicalActive
Key Facts
About Lexaria Bioscience
Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Haptenized Viral Vaccines | BioVaxys | Preclinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| RECCE® 529 | Recce Pharmaceuticals | Preclinical |